Associations between change in BMI and the risk of hypertension and dyslipidaemia in people receiving integrase strand-transfer inhibitors, tenofovir alafenamide, or both compared with other contemporary antiretroviral regimens: a multicentre, prospective observational study from the RESPOND consortium cohorts.

Saved in:
Bibliographic Details
Title: Associations between change in BMI and the risk of hypertension and dyslipidaemia in people receiving integrase strand-transfer inhibitors, tenofovir alafenamide, or both compared with other contemporary antiretroviral regimens: a multicentre, prospective observational study from the RESPOND consortium cohorts.
Authors: Byonanebye DM; Kirby Institute, University of New South Wales, Kensington, NSW, Australia; School of Public Health, Makerere University, Kampala, Uganda. Electronic address: dbyonanebye@musph.ac.ug., Polizzotto MN; The Australian National University, Canberra, ACT, Australia., Maltez F; Hospital Curry Cabral, Lisbon, Portugal., Rauch A; Department of Infectious Diseases, Inselspital, Bern University Hospital, Bern, Switzerland., Grabmeier-Pfistershammer K; Medizinische Universität Wien, Vienna, Austria., Wit F; Stichting HIV Monitoring, Amsterdam, Netherlands., De Wit S; Department of Infectious Diseases, St Pierre University Hospital Bruxelles, Université Libre de Bruxelles, Brussels, Belgium., Castagna A; San Raffaele Scientific Institute, Università Vita-Salute San Raffaele, Milan, Italy., d'Arminio Monforte A; ASST Santi Paolo e Carlo, Milan, Italy., Mussini C; Università degli Studi di Modena, Modena, Italy., Wasmuth JC; University Hospital Bonn, Bonn, Germany., Fontas E; Nice HIV cohort, Université Côte d'Azur et Centre Hospitalier Universitaire, Nice, France., Abela I; University of Zurich, Zurich, Switzerland; University Hospital of Zurich, Zurich, Switzerland., Sarcletti M; Department of Dermatology, Venerology, and Allergology, Medical University Innsbruck, Innsbruck, Austria., Bansi-Matharu L; Center for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, University College London, London, UK., Jaschinski N; CHIP, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark., Peters L; CHIP, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark., Hosein SR; European AIDS Treatment Group, Brussels, Belgium., Vannappagari V; ViiV Healthcare, Durham, NC, USA., Cohen C; Gilead Sciences, Foster City, CA, USA., Bissio E; Merck Sharp & Dohme, Madrid, Spain., Mocroft A; Center for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, University College London, London, UK; CHIP, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark., Law M; Kirby Institute, University of New South Wales, Kensington, NSW, Australia., Ryom L; CHIP, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark., Petoumenos K; Kirby Institute, University of New South Wales, Kensington, NSW, Australia.
Corporate Authors: RESPOND study group
Source: The lancet. HIV [Lancet HIV] 2024 May; Vol. 11 (5), pp. e321-e332. Date of Electronic Publication: 2024 Apr 12.
Publication Type: Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural
Journal Info: Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101645355 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2352-3018 (Electronic) Linking ISSN: 23523018 NLM ISO Abbreviation: Lancet HIV Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2352-3018
DOI:10.1016/S2352-3018(23)00328-4